S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NYSEAMERICAN:NSPR - InspireMD Stock Price, Forecast & News

$1.36
+0.20 (+17.24 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$1.23
Now: $1.36
$1.64
50-Day Range
$1.34
MA: $2.42
$3.59
52-Week Range
$0.74
Now: $1.36
$11.35
Volume3.44 million shs
Average Volume484,325 shs
Market Capitalization$4.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NSPR
Previous SymbolNASDAQ:NSPR
CUSIPN/A
Phone+1-857-4536553

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees43
Market Cap$4.94 million
Next Earnings Date2/18/2020 (Estimated)
OptionableNot Optionable

Receive NSPR News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.


Why Firing Your Internet Provider Could Save You $19,494 (Ad)


A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

InspireMD (NYSEAMERICAN:NSPR) Frequently Asked Questions

What is InspireMD's stock symbol?

InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."

When did InspireMD's stock split? How did InspireMD's stock split work?

InspireMD shares reverse split before market open on Monday, April 1st 2019. The 1-50 reverse split was announced on Tuesday, March 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 29th 2019. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 2 shares after the split.

How were InspireMD's earnings last quarter?

InspireMD Inc (NYSEAMERICAN:NSPR) released its earnings results on Tuesday, November, 12th. The medical equipment provider reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.35) by $0.09. The medical equipment provider had revenue of $0.94 million for the quarter, compared to analyst estimates of $1.40 million. View InspireMD's Earnings History.

When is InspireMD's next earnings date?

InspireMD is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for InspireMD.

What guidance has InspireMD issued on next quarter's earnings?

InspireMD issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1-1.025 million, compared to the consensus revenue estimate of $1.6 million.

What price target have analysts set for NSPR?

1 analysts have issued 1-year target prices for InspireMD's shares. Their forecasts range from $5.00 to $5.00. On average, they expect InspireMD's share price to reach $5.00 in the next year. This suggests a possible upside of 267.6% from the stock's current price. View Analyst Price Targets for InspireMD.

What is the consensus analysts' recommendation for InspireMD?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InspireMD.

What are Wall Street analysts saying about InspireMD stock?

Here are some recent quotes from research analysts about InspireMD stock:
  • 1. According to Zacks Investment Research, "InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel. " (11/21/2019)
  • 2. HC Wainwright analysts commented, "Our $5 PT was derived by using a 25% weighted-average cost of capital to discount free cash flows we project 2019-2030, and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then ascribing a 1% terminal growth rate and 75% probability of." (8/19/2019)

Has InspireMD been receiving favorable news coverage?

Press coverage about NSPR stock has been trending very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. InspireMD earned a news impact score of -3.6 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for InspireMD.

Who are some of InspireMD's key competitors?

What other stocks do shareholders of InspireMD own?

Who are InspireMD's key executives?

InspireMD's management team includes the folowing people:
  • Dr. James J. Barry, Pres, CEO & Director (Age 60)
  • Mr. Craig Shore, CFO, Chief Admin. Officer, Sec. & Treasurer (Age 58)
  • Mr. Agustin V. Gago, Exec. VP & Chief Commercial Officer (Age 59)
  • Mr. Roei Samuri, VP of Operations
  • Dr. Sol J. Barer, Special Advisor to the Board (Age 72)

Who are InspireMD's major shareholders?

InspireMD's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (1.67%). Company insiders that own InspireMD stock include Paul Stuka and Thomas J Kester. View Institutional Ownership Trends for InspireMD.

Which major investors are buying InspireMD stock?

NSPR stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for InspireMD.

How do I buy shares of InspireMD?

Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is InspireMD's stock price today?

One share of NSPR stock can currently be purchased for approximately $1.36.

How big of a company is InspireMD?

InspireMD has a market capitalization of $4.94 million. InspireMD employs 43 workers across the globe.View Additional Information About InspireMD.

What is InspireMD's official website?

The official website for InspireMD is http://www.inspiremd.com/.

How can I contact InspireMD?

InspireMD's mailing address is 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel. The medical equipment provider can be reached via phone at +1-857-4536553.


MarketBeat Community Rating for InspireMD (NYSEAMERICAN NSPR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote "Outperform" if you believe NSPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel